Compare VSTS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VSTS | RAPP |
|---|---|---|
| Founded | 1936 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2023 | 2024 |
| Metric | VSTS | RAPP |
|---|---|---|
| Price | $14.56 | $41.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.88 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.2M | 354.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,734,839,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $13.64 |
| 52 Week High | $16.90 | $44.28 |
| Indicator | VSTS | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 51.35 |
| Support Level | $13.40 | $38.55 |
| Resistance Level | $15.06 | $43.89 |
| Average True Range (ATR) | 0.61 | 2.43 |
| MACD | -0.22 | -0.10 |
| Stochastic Oscillator | 11.72 | 42.93 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.